Latest CSL (ASX:CSL) News

CSL Limited’s latest Capital Markets Day presentation highlights CSL Seqirus’s strategic positioning to capitalize on a recovering US influenza vaccine market and global growth opportunities.

CSL Limited has revised its financial outlook for FY26, citing lower US influenza vaccination rates and government cost controls in China, while postponing the planned demerger of its Seqirus vaccine business and announcing a major cost-saving program.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

CSL Limited has updated its dividend announcement for the first half of FY2025, confirming a USD 1.62 per share ordinary dividend and clarifying currency payment arrangements for global shareholders.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.

CSL Limited has announced an unfranked ordinary dividend of USD 1.62 per share for the first half of 2025, with payments scheduled in multiple currencies depending on shareholder location.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.

CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.

CSL Limited has announced a USD 1.30 per share dividend for the half-year ending December 2024, marking a steady return for investors despite the payout being fully unfranked.

CSL Limited reported a solid half-year performance with 5% revenue growth and a 7% rise in net profit, driven by strong demand in its Behring and Vifor segments despite challenges in Seqirus. The company reaffirmed its full-year NPATA guidance of 10-13%, signaling confidence in its operational momentum.

CSL Limited posted a robust half-year performance with NPATA rising 5% at constant currency, driven by strong growth in CSL Behring and CSL Vifor despite challenges in its influenza vaccine segment. The company reaffirmed its FY25 guidance, anticipating double-digit earnings growth.